Benjamin Darbro, MD, PhD at the University of Iowa, uses VarSeq® software for Clinical Testing

Founded by Hans Zellweger in the 1960’s, The Shivanand R. Patil Cytogenetics and Molecular Lab at the University of Iowa has a long history of clinical testing, seeing 45 years of advancements. Today, the lab is mainly focused on oncology, pre and post-natal genetics testing and serves the University of Iowa Hospitals and Clinics as well as the University of Iowa Stead Family Children’s Hospital. In last year alone they have performed over 5,500 clinical tests.

When the lab’s director, Dr. Benjamin Darbro purchased Illumina’s NextSeq 500, he did so with the vision of being able to offer phenotype-focused gene sequencing panels. Darbro knew this goal would require an informatics pipeline with the same level of sophistication the lab developed for their research side, but one that would fit within the framework required of clinical testing. The decision then was between developing their own testing pipeline or to choose a vendor solution. “In order to develop and handle our own pipeline, it required somebody like me with a bioinformatics background,” commented Darbro. “Command-line interface isn’t very user-friendly or approachable for most of the people in the lab. We needed something that kept a lot of the really hardcore bioinformatics components under the hood, but still had the power and sophistication that we had grown accustomed to on the research side.” Darbro also considered the effort in maintaining the system they chose. “By paying for software, we’re really partnering with an organization in such a way that a lot of the burden is now off of us, as far as maintaining and updating the tools, databases and sources of information.”

Ultimately, Darbro decided that a commercial software package would best meet the lab’s needs and created a list of criteria in which to evaluate their options. “When it came to the tertiary analysis portion, we looked at Tute Genomics, Cartagenia, CLC Genomics Workbench and VarSeq,” Ben explained. In the end, it was a simple quantitative decision for Darbro. Darbro states, “VarSeq had everything we were looking for with regards to annotation, filtering sources and an actual visual browser within the software itself. VSReports allows us to take it all the way to the report generation. But what really set it apart in retrospect is how intuitive it is.” Darbro explained that of the 17 lab techs, 2 clinical cytogeneticist fellows and numerous residents and students, it has been rare for anyone to contact support for training. “It’s the kind of phenomenon that you see when people are using an iPhone,” Ben commented. “They just kind of understand how it works naturally, because the design is so good.” In an environment where the level of testing complexity is so high, anything that lowers that bar of accessibility is a remarkable acquisition in Dr. Darbro’s opinion.

VarSeq has also brought benefit to the research operations of Shivanand R. Patil Lab. In the past, when working with collaborators, data would be run through the lab’s custom pipeline and then sent back to their clients.

QUICK FACTS:
Name: Benjamin Darbro, MD, PhD
Title: Director
Institution: Shivanand R. Patil Cytogenetics and Molecular Laboratory
Location: Iowa City, Iowa
Services Provided: Clinical Cytogenetics & Molecular Genetic Pathology
Data: Phenotype-focused gene sequencing panels
Golden Helix Software: VarSeq Clinical Suite
About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over 17 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With our solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 900 peer-reviewed publications.